Autolus Therapeutics, which is developing blood cancer therapies based on highly targeted CAR T cells, raised $150 million by offering 8.8 million shares at $17, the high end of the $15 to $17 range. The company planned to offer 7.8 million shares. Existing investors intended o buy up to $60 million on the IPO.
Autolus Therapeutics plans to list on the Nasdaq under the symbol AUTL. Goldman Sachs and Jefferies acted as lead managers on the deal.
